ChiCTR2000032241 版本V1.2 版本创建时间2020/04/24 03:10:38 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000032241 

最近更新日期:

Date of Last Refreshed on:

2020-04-24 03:09:45 

注册时间:

Date of Registration:

2020-04-24 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

冠心V号治疗冠心病的安全性和有效性:基于病历记录的研究

Public title:

Guanxin V for coronary artery disease: a medical records based retrospective study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

冠心V号治疗冠心病的安全性和有效性研究

Scientific title:

Guanxin V for coronary artery disease: a retrospective study

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

梁波 

研究负责人:

顾宁 

Applicant:

Bo Liang 

Study leader:

Ning Gu 

申请注册联系人电话:

Applicant telephone:

+86 15181400995

研究负责人电话:

Study leader's telephone:

+86 15181400995

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

liangbo2018@126.com

研究负责人电子邮件:

Study leader's E-mail:

jsguning@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

江苏省南京市栖霞区仙林大道138号

研究负责人通讯地址:

江苏省南京市秦淮区大明路157号

Applicant address:

138 Xianlin Avenue, Qixia District, Nanjing, Jiangsu

Study leader's address:

157 Daming Road, Qinhuai Distrcit, Nanjing, Jiangsu

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

南京中医药大学

Applicant's institution:

Nanjing University of Chinese Medicine

研究负责人所在单位:

南京中医药大学

Affiliation of the Leader:

Nanjing University of Chinese Medicine

是否获伦理委员会批准:

否/No

Approved by ethic committee:

No

伦理委员会批件文号:

Approved No. of ethic committee:

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

Name of the ethic committee:

伦理委员会批准日期:

Date of approved by ethic committee:

2013-08-26 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

南京中医药大学附属南京中医院

Primary sponsor:

Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine

研究实施负责(组长)单位地址:

江苏省南京市秦淮区大明路157号

Primary sponsor's address:

157 Daming Road, Qinhuai Distrcit, Nanjing, Jiangsu

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏省

市(区县):

南京市

Country:

China

Province:

Jiangsu

City:

Nanjing

单位(医院):

南京中医药大学附属南京中医院

具体地址:

江苏省南京市秦淮区大明路157号

Institution
hospital:

Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine

Address:

157 Daming Road, Qinhuai Distrcit, Nanjing, Jiangsu

经费或物资来源:

国自然面上项目

Source(s) of funding:

National Natural Science Foundation of China

Target disease:

Coronary artery disease

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

回顾性研究 

Study phase:

Retrospective study

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

冠心V号为南京中医药大学附属南京中医院院内制剂,已获得国家发明专利(ZL200710019749.0),临床上用于治疗冠心病,疗效显著。本试验通过回顾性分析,以评估冠心V号治疗冠心病的疗效性和安全性。  

Objectives of Study:

Guanxin V (GXV) is an in-hospital preparation of Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine. It has obtained a national invention patent (ZL200710019749.0) and is used clinically to treat coronary heart disease (CAD), with a significant effect. This is a retrospective study to evaluate the efficacy and safety of GXV for CAD.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.成年人; 2.符合西医冠心病诊断标准; 3.符合中医气阴两虚夹淤证诊断标准。

Inclusion criteria

1. Adults. 2. Meet the diagnostic criteria of CAD. 3. Meet the diagnostic criteria of Qi and Yin deficiency and blood stasis.

排除标准:

近2周有服用中药史。

Exclusion criteria:

Continuation of any form of Chinese herbal medicines for 14 days before enrollment.

研究实施时间:

Study execute time:

From 2006-12-01 00:00:00 To 2009-01-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-04-20 00:00:00 To 2020-05-31 00:00:00  

干预措施:

Interventions:

组别:

冠心V号组

样本量:

50

Group:

GXV group

Sample size:

干预措施:

冠心V号

干预措施代码:

Intervention:

GXV

Intervention code:

组别:

常规治疗组

样本量:

50

Group:

GMT group

Sample size:

干预措施:

常规治疗组

干预措施代码:

Intervention:

Convenience treatment

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏 

市(区县):

南京 

Country:

China 

Province:

Jiangsu 

City:

Nanjing 

单位(医院):

南京中医药大学附属南京中医院 

单位级别:

三甲医院 

Institution
hospital:

Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

中医证候积分

指标类型:

主要指标

Outcome:

Traditional Chinese medicine syndrome score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心功能评价

指标类型:

主要指标

Outcome:

Heart function

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

不良事件

指标类型:

主要指标

Outcome:

Adverse events

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血样

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

回顾性研究

Randomization Procedure (please state who generates the random number sequence and by what method):

This is a retrospective study

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

联系项目负责人

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

E-mail the study leader

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2020-04-24 01:44:16